What is the immediate outlook for 1093.HK stock after the pre-market move?

Short-term outlook is cautious: the stock is down **5.34%** pre-market and technicals show RSI **34.78**. Earnings guidance will likely drive intraday volatility and determine the next directional move.

How does Meyka AI value 1093.HK stock and what is the grade?

Meyka AI rates 1093.HK **70.69/100**, Grade **B+**, suggestion **BUY**. The grade combines benchmark, sector, growth, and metric analysis. This is informational and not investment advice.

What price targets and upside does the model show for 1093.HK stock?

Meyka AI's forecast model projects **HK$12.22** for one year, implying **46.66%** upside from **HK$8.33**. Monthly and quarterly figures are **HK$9.90** and **HK$11.70** respectively; forecasts are model-based projections.

What risks should investors track for 1093.HK stock around earnings?

Key risks are weaker-than-expected revenue, margin compression, slower product launches, and any slowdown in royalty or partnership receipts. Watch cash flow and management commentary on R&D spend.

HK Stocks

1093.HK CSPC Pharmaceutical (HKSE) down pre-market before 25 Mar 2026 earnings: watch guidance

ByHuzaifa Zahoor March 24, 2026March 24, 2026

1093.HK stock opened at HK$8.45 and trades at HK$8.33 pre-market, down 5.34% as investors position ahead of CSPC Pharmaceutical Group Limited’s earnings due 25 Mar 2026. The sell-off follows heavier intraday volume of 99,301,497 shares against a 50-day average price of HK$9.69. Key figures to watch in the report are EPS 0.38, P/E 21.76, and guidance on oncology and metabolic partnerships. We use Meyka AI’s real-time signals and sector context to frame the earnings risk and potential upside for Hong Kong-listed CSPC on the HKSE.